SMLR Stock Overview
Provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Semler Scientific, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$61.78 |
| 52 Week High | US$81.56 |
| 52 Week Low | US$20.88 |
| Beta | 1.18 |
| 1 Month Change | -2.94% |
| 3 Month Change | 177.04% |
| 1 Year Change | 42.98% |
| 3 Year Change | -32.71% |
| 5 Year Change | 23.56% |
| Change since IPO | 783.83% |
Recent News & Updates
Recent updates
Semler Scientific: Booking Some Profits After Bitcoin Strategy
Dec 10Semler Scientific, Inc. (NASDAQ:SMLR) Held Back By Insufficient Growth Even After Shares Climb 27%
Nov 02
Earnings Troubles May Signal Larger Issues for Semler Scientific (NASDAQ:SMLR) Shareholders
Aug 14The Market Doesn't Like What It Sees From Semler Scientific, Inc.'s (NASDAQ:SMLR) Earnings Yet
Jul 18We Ran A Stock Scan For Earnings Growth And Semler Scientific (NASDAQ:SMLR) Passed With Ease
May 08Many Still Looking Away From Semler Scientific, Inc. (NASDAQ:SMLR)
Apr 17Is Now The Time To Put Semler Scientific (NASDAQ:SMLR) On Your Watchlist?
Jan 11Estimating The Intrinsic Value Of Semler Scientific, Inc. (NASDAQ:SMLR)
Dec 07What Does Semler Scientific, Inc.'s (NASDAQ:SMLR) Share Price Indicate?
Apr 07Calculating The Intrinsic Value Of Semler Scientific, Inc. (NASDAQ:SMLR)
Dec 14Semler Scientific: Growth, Profits, And Valuation Models Support A Buy
Aug 02Semler Scientific: A Small Company Solving A Big Problem
Apr 21Things Look Grim For Semler Scientific, Inc. (NASDAQ:SMLR) After Today's Downgrade
Mar 08Semler Scientific: Why I'm Buying
Mar 05Should You Investigate Semler Scientific, Inc. (NASDAQ:SMLR) At US$52.64?
Mar 02Semler's Unique Business Model Is Fueling Profitable Growth
Feb 23Better Price For Semler Is Likely
Jan 05Semler Scientific's (NASDAQ:SMLR) Earnings Are Weaker Than They Seem
Nov 12Shareholder Returns
| SMLR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -8.0% | -1.5% | -2.4% |
| 1Y | 43.0% | 10.1% | 23.3% |
Return vs Industry: SMLR exceeded the US Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: SMLR exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| SMLR volatility | |
|---|---|
| SMLR Average Weekly Movement | 18.9% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SMLR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SMLR's weekly volatility has increased from 13% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 92 | Doug Murphy-Chutorian | www.semlerscientific.com |
Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing.
Semler Scientific, Inc. Fundamentals Summary
| SMLR fundamental statistics | |
|---|---|
| Market cap | US$512.07m |
| Earnings (TTM) | US$15.91m |
| Revenue (TTM) | US$58.94m |
32.2x
P/E Ratio8.7x
P/S RatioIs SMLR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SMLR income statement (TTM) | |
|---|---|
| Revenue | US$58.94m |
| Cost of Revenue | US$7.04m |
| Gross Profit | US$51.90m |
| Other Expenses | US$35.98m |
| Earnings | US$15.91m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.92 |
| Gross Margin | 88.05% |
| Net Profit Margin | 27.00% |
| Debt/Equity Ratio | 0% |
How did SMLR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:31 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Semler Scientific, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| Marc Wiesenberger | B. Riley Securities, Inc. |
| Yi Chen | H.C. Wainwright & Co. |